| Name | Title | Contact Details |
|---|
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
Yamanouchi Pharma Ttechnologies, Inc. is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lexigen is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.
Melior Discovery Inc (Exton, PA, USA) has pioneered a unique high throughput in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development stage drugs. theraTRACE® is widely used by both multinational pharmaceutical and start-up biopharmaceutical companies alike to fully explore the therapeutic potential of their drug candidates. Melior has also leveraged this expertise to build a high quality, onshore, preclinical services capability offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models and bioanalytical services to drug developers worldwide.